Zhu Li, Zhang Yan-Jun, Wang Bin, Yang Li, Zheng Yi-Qiong, Sun Lin-De, Tian Lin, Chen Tao, Wang Jian-Dong
Department of General Surgery, The First Medical Center of Peoples Liberation Army General Hospital, Beijing, China.
Department of General Surgery, The Second Medical Center of Peoples Liberation Army General Hospital, Beijing, China.
Front Oncol. 2021 Jul 19;11:660307. doi: 10.3389/fonc.2021.660307. eCollection 2021.
Breast cancer is one of the most common life-threatening cancers, mainly because of its aggressiveness and metastasis. Accumulating evidence indicates that long non-coding RNAs (lncRNAs) participate in the development and progression of breast cancer. Nevertheless, the function and expression level of lncRNAs in breast cancer are still not fully understood. Here, we demonstrated that lncRNA PCDHB17P was up-expressed in human breast cancer tissues and cell lines. Knockdown of PCDHB17P remarkably suppressed migration and invasion, as well as tube formation ability of breast cancer cells. MiR-145-3p was significantly decreased in breast cancer samples, which was negatively correlated to the expression of PCDHB17P. In addition, we identified that MELK was a direct target gene of miR-145-3p, which was higher expressed in breast cancer tissues than that in adjacent normal tissues. Mechanistic investigation indicated that PCDHB17P acted as a cancer-promoting competing endogenous RNA (ceRNA) by binding miR-145-3p and upregulating MELK. Interestingly, MELK could in turn increase the promoter activity and expression of PCDHB17P NF-κB, thus forming a positive feedback loop that drives the metastasis and angiogenesis of breast cancer. Overall, the results demonstrated that the constitutive activation of PCDHB17P/miR-145-3p/MELK/NF-κB feedback loop promotes the metastasis and angiogenesis of breast cancer, suggesting that this lncRNA might be a promising prognostic biomarker and therapeutic target for breast cancer.
乳腺癌是最常见的危及生命的癌症之一,主要因其侵袭性和转移性。越来越多的证据表明,长链非编码RNA(lncRNA)参与乳腺癌的发生和发展。然而,lncRNA在乳腺癌中的功能和表达水平仍未完全明确。在此,我们证明lncRNA PCDHB17P在人乳腺癌组织和细胞系中高表达。敲低PCDHB17P可显著抑制乳腺癌细胞的迁移、侵袭及管腔形成能力。miR-145-3p在乳腺癌样本中显著降低,且与PCDHB17P的表达呈负相关。此外,我们鉴定出MELK是miR-145-3p的直接靶基因,其在乳腺癌组织中的表达高于相邻正常组织。机制研究表明,PCDHB17P通过结合miR-145-3p并上调MELK,作为一种促癌竞争性内源RNA(ceRNA)发挥作用。有趣的是,MELK反过来可增加PCDHB17P的启动子活性和表达 NF-κB,从而形成一个驱动乳腺癌转移和血管生成的正反馈环。总体而言,结果表明PCDHB17P/miR-145-3p/MELK/NF-κB反馈环的组成性激活促进乳腺癌的转移和血管生成,提示该lncRNA可能是一种有前景的乳腺癌预后生物标志物和治疗靶点。